Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy

Blood

Volumn 124, Issue 18, 2014, Pages 2824-2833

  Heczey, Andras ^a   Liu, Daofeng ^a   Tian, Gengwen ^a   Courtney, Amy N ^a   Wei, Jie ^a   Marinova, Ekaterina ^a   Gao, Xiuhua ^a   Guo, Linjie ^a   Yvon, Eric ^b   Hicks, John ^a   Liu, Hao ^a   Dotti, Gianpietro ^a,b   Metelitsa, Leonid S ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD1D ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD3 ANTIGEN ZETA; CHIMERIC ANTIGEN RECEPTOR; GANGLIOSIDE GD2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; CANCER VACCINE; CD137 LIGAND; CYTOKINE; GANGLIOSIDE; GANGLIOSIDE, GD2; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL POLARITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LONG TERM SURVIVAL; METASTASIS; MOUSE; NATURAL KILLER T CELL; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; TH1 CELL; ANIMAL; CELL LINE; CELL PROLIFERATION; CHEMISTRY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MACROPHAGE; METABOLISM; NEUROBLASTOMA; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; RETROVIRUS; TREATMENT OUTCOME;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD1D; ANTIGENS, CD28; CANCER VACCINES; CELL LINE; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GANGLIOSIDES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; NATURAL KILLER T-CELLS; NEOPLASM METASTASIS; NEUROBLASTOMA; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN; RETROVIRIDAE; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

EID: 84908612560     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-541235     Document Type: Article

References (51)

1. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013; 39(1):49-60.
2. Dotti G, Gottschalk S, Savoldo B., Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014; 257(1):107-126.
3. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002; 20(1):70-75.
4. Imai C, Mihara K, Andreansky M., et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004; 18(4):676-684.
5. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013; 3(4):388-398.
6. Porter DL, Levine BL, Kalos M, Bagg A., June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-733.
7. Grupp SA, Kalos M, Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16): 1509-1518.
8. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38.
9. Kochenderfer JN, Dudley ME, Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119(12): 2709-2720.
10. June C, Rosenberg SA, Sadelain M, Weber JS. T-cell therapy at the threshold. Nat Biotechnol. 2012; 30(7):611-614.
11. Gilham DE, Debets R, Pule M., Hawkins RE, Abken H. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med. 2012; 18(7):377-384.
12. Shiao SL, Ganesan AP, Rugo H.S., Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011; 25(24): 2559-2572.
13. Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?" Hum Gene Ther. 2009; 20(11):1229-1239.
14. Pule MA, Savoldo B, Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-1270.
15. Louis CU, Savoldo B, Dotti G., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011; 118(23):6050-6056.
16. Metelitsa LS, Wu HW, Wang H, et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004; 199(9): 1213-1221.
17. Tachibana T, Onodera H, Tsuruyama T., et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res. 2005; 11(20):7322-7327.
18. Brossay L, Chioda M, Burdin N., et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998; 188(8):1521-1528.
19. Ulanova M, Tarkowski A, Porcelli S.A., Hanson LA. Antigen-specific regulation of CD1 expression in humans. J Clin Immunol. 2000; 20(3):203-211.
20. Liu D, Song L, Wei J., et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012; 122(6):2221-2233.
21. Allavena P, Sica A, Solinas G., Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008; 66(1):1-9.
22. Song L, Asgharzadeh S, Salo J., et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest. 2009; 119(6):1524-1536.
23. Exley MA, Hou R, Shaulov A., et al. Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol. 2008; 38(6):1756-1766.
24. Reynolds CP, Tomayko MM, Donner L, et al. Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res. 1988; 271:291-306.
25. Song L, Ara T, Wu H.W., et al. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest. 2007; 117(9):2702-2712.
26. Metelitsa LS, Naidenko OV, Kant A, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001; 167(6):3114-3122.
27. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005; 12(5):933-941.
28. Vera J, Savoldo B, Vigouroux S., et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006; 108(12):3890-3897.
29. Rooney CM, Rickinson AB, Moss D.J., Lenoir GM, Epstein MA. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer. 1984; 34(3):339-348.
30. Holleczek B, Brenner H. Model based period analysis of absolute and relative survival with R: data preparation, model fitting and derivation of survival estimates. Comput Methods Programs Biomed. 2013; 110(2):192-202.
31. Rossig C, Bollard CM, Nuchtern J.G., Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001; 94(2):228-236.
32. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol. 2002; 2(8):557-568.
33. Swann JB, Coquet JM, Smyth M.J., Godfrey DI. CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol. 2007; 314:293-323.
34. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (). Annu Rev Immunol. 2010; 28:445-489.
35. Bridgeman JS, Ladell K, Sheard V.E., et al. CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. Clin Exp Immunol. 2014; 175(2):258-267.
36. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M., Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 2010; 184(12):6938-6949.
37. Asgharzadeh S, Salo JA, Ji L, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012; 30(28):3525-3532.
38. Metelitsa LS. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol. 2011; 140(2):119-129.
39. King MA, Covassin L, Brehm M.A., et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol. 2009; 157(1):104-118.
40. Song DG, Ye Q, Carpenito C., et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011; 71(13):4617-4627.
41. Davila ML, Riviere I, Wang X., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25.
42. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003; 9(3):279-286.
43. Matsuda JL, Gapin L, Baron J.L., et al. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA. 2003; 100(14):8395-8400.
44. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011; 121(5):1822-1826.
45. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013; 13(8):525-541.
46. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013; 10(5):267-276.
47. Rapoport AP, Stadtmauer EA, Aqui N, et al. Rapid immune recovery and graft-versus-host diseaselike engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res. 2009; 15(13):4499-4507.
48. Pillai AB, George TI, Dutt S, Teo P., Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol. 2007; 178(10):6242-6251.
49. Morris ES, MacDonald KP, Rowe V, et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest. 2005; 115(11):3093-3103.
50. de Lalla C, Rinaldi A, Montagna D., et al. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4-subset dynamics and correlates with remission state. J Immunol. 2011; 186(7):4490-4499.
51. Casorati G, de Lalla C, Dellabona P. Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation. OncoImmunology. 2012; 1(3):355-357.